{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T10:55:18Z","timestamp":1792839318279,"version":"4.5.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2069,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,1]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>\n                                 <jats:bold>Terlipressin plus albumin is an effective treatment for type 1 hepatorenal syndrome (HRS), but approximately only half of the patients respond to this therapy. The aim of this study was to assess predictive factors of response to treatment with terlipressin and albumin in patients with type 1 HRS. Thirty-nine patients with cirrhosis and type 1 HRS were treated prospectively with terlipressin and albumin. Demographic, clinical, and laboratory variables obtained before the initiation of treatment as well as changes in arterial pressure during treatment were analyzed for their predictive value. Response to therapy (reduction in serum creatinine &lt;1.5 mg\/dL at the end of treatment) was observed in 18 patients (46%) and was associated with an improvement in circulatory function. Independent predictive factors of response to therapy were baseline serum bilirubin and an increase in mean arterial pressure of \u22655 mm Hg at day 3 of treatment. The cutoff level of serum bilirubin that best predicted response to treatment was 10 mg\/dL (area under the receiver operating characteristic curve, 0.77;<\/jats:bold>\n                                 <jats:bold>\n                                    P\n                                 <\/jats:bold>\n                                 <jats:bold>&lt; 0.0001; sensitivity, 89%; specificity, 61%). Response rates in patients with serum bilirubin &lt;10 mg\/dL or \u226510 mg\/dL were 67% and 13%, respectively (<\/jats:bold>\n                                 <jats:bold>\n                                    P\n                                 <\/jats:bold>\n                                 <jats:bold>= 0.001). Corresponding values in patients with an increase in mean arterial pressure \u22655 mm Hg or &lt;5 mm Hg at day 3 were 73% and 36%, respectively (<\/jats:bold>\n                                 <jats:bold>\n                                    P\n                                 <\/jats:bold>\n                                 <jats:bold>= 0.037).<\/jats:bold>\n                                 <jats:bold>\n                                    Conclusion:\n                                 <\/jats:bold>\n                                 <jats:bold>Serum bilirubin and an early increase in arterial pressure predict response to treatment with terlipressin and albumin in type 1 HRS. Alternative treatment strategies to terlipressin and albumin should be investigated for patients with type 1 HRS and low likelihood of response to vasoconstrictor therapy. (Hepatology 2009.)<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.23283","type":"journal-article","created":{"date-parts":[[2009,9,9]],"date-time":"2009-09-09T14:15:33Z","timestamp":1252505733000},"page":"219-226","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":200,"title":["Predictors of Response to Therapy With Terlipressin and Albumin in Patients With Cirrhosis and Type 1 Hepatorenal Syndrome"],"prefix":"10.1097","volume":"51","author":[{"given":"Andr\u00e9","family":"Nazar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo Henrique","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Guevara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Mart\u00edn-Llahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-No\u00eblle","family":"Pepin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Marinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Sol\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Eugenia","family":"Baccaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Terra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Arroyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pere","family":"Gin\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-27-20241201","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1055\/s-2008-1040323","article-title":"Pathogenesis and treatment of hepatorenal syndrome.","volume":"28","author":"Arroyo","year":"2008","journal-title":"Semin Liver Dis"},{"key":"R3-27-20241201","first-page":"1310","article-title":"Diagnosis, prevention and treatment of the hepatorenal syndrome in cirrhosis. A consensus workshop of the international ascites club.","volume":"56","author":"Salerno","year":"2007","journal-title":"Gut"},{"key":"R4-27-20241201","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1053\/jhep.2003.50084","article-title":"Acute renal failure in patients with cirrhosis: perspectives in the age of MELD.","volume":"37","author":"Moreau","year":"2003","journal-title":"HEPATOLOGY"},{"key":"R5-27-20241201","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/gut.49.5.729","article-title":"The hepatorenal syndrome.","volume":"49","author":"Dagher","year":"2001","journal-title":"Gut"},{"key":"R6-27-20241201","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/00007890-199502150-00010","article-title":"Impact of pretransplant renal function on survival after liver transplantation.","volume":"59","author":"Gonwa","year":"1995","journal-title":"Transplantation"},{"key":"R7-27-20241201","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1097\/00007890-199712270-00024","article-title":"Hepatorenal syndrome: combined liver kidney transplants versus isolated liver transplant.","volume":"64","author":"Jeyarajah","year":"1997","journal-title":"Transplantation"},{"key":"R8-27-20241201","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1053\/jhep.2002.33160","article-title":"Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation.","volume":"35","author":"Nair","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R9-27-20241201","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/ndt\/gfi212","article-title":"The course of type 1 hepatorenal syndrome post liver transplantation.","volume":"21","author":"Marik","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"R10-27-20241201","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/lt.21149","article-title":"Hepatorenal syndrome: a proposal for kidney after liver transplantation (KALT).","volume":"13","author":"Ruiz","year":"2007","journal-title":"Liver Transpl"},{"key":"R12-27-20241201","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/hep.21094","article-title":"The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond.","volume":"43","author":"Moreau","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R13-27-20241201","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/j.1365-2036.2006.03086.x","article-title":"Metaanalysis: terlipressin therapy for the hepatorenal syndrome.","volume":"24","author":"Fabrizi","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"R14-27-20241201","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(03)14903-3","article-title":"Hepatorenal syndrome.","volume":"362","author":"Gines","year":"2003","journal-title":"Lancet"},{"key":"R15-27-20241201","first-page":"164","article-title":"Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club.","volume":"23","author":"Arroyo","year":"1996","journal-title":"HEPATOLOGY"},{"key":"R16-27-20241201","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0168-8278(00)80158-0","article-title":"Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome.","volume":"33","author":"Uriz","year":"2000","journal-title":"J Hepatol"},{"key":"R17-27-20241201","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1053\/jhep.2002.35819","article-title":"Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study.","volume":"36","author":"Ortega","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R18-27-20241201","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1053\/j.gastro.2008.02.024","article-title":"Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.","volume":"134","author":"MartinLlahi","year":"2008","journal-title":"Gastroenterology"},{"key":"R19-27-20241201","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.1016\/j.jhep.2004.12.007","article-title":"Management of complications of cirrhosis in patients awaiting liver transplantation.","volume":"42","author":"Cardenas","year":"2005","journal-title":"J Hepatol"},{"key":"R20-27-20241201","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"R21-27-20241201","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1053\/j.gastro.2008.02.014","article-title":"A randomized, prospective, doubleblind, placebocontrolled trial of terlipressin for type 1 hepatorenal syndrome.","volume":"134","author":"Sanyal","year":"2008","journal-title":"Gastroenterology"},{"key":"R22-27-20241201","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1046\/j.1440-1746.2002.02816.x","article-title":"Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with terlipressin: a retrospective analysis.","volume":"17","author":"Colle","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"key":"R23-27-20241201","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jhep.2007.04.010","article-title":"Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study.","volume":"47","author":"Alessandria","year":"2007","journal-title":"J Hepatol"},{"key":"R24-27-20241201","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1007\/s10620-007-9919-9","article-title":"Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.","volume":"53","author":"Neri","year":"2008","journal-title":"Dig Dis Sci"},{"key":"R25-27-20241201","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/j.1572-0241.2008.01828.x","article-title":"An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response.","volume":"103","author":"Sharma","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"R26-27-20241201","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1053\/gast.2002.32364","article-title":"Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study.","volume":"122","author":"Moreau","year":"2002","journal-title":"Gastroenterology"},{"key":"R28-27-20241201","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jhep.2003.09.019","article-title":"Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A casecontrol study.","volume":"40","author":"Restuccia","year":"2004","journal-title":"J Hepatol"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.23283","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201001000-00027","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T13:41:56Z","timestamp":1733060516000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201001000-00027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.23283","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}